期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

宫颈癌组织中RRM1的表达及意义 被引量：3

Expression and significance of RRM1 in uterine cervical cancer tissue
下载PDF
导出
摘要 目的探讨RRM1在宫颈癌组织中的表达水平与宫颈癌发生、发展的关系。方法应用免疫组织化学方法检测RRM1蛋白在80例宫颈癌组织、30例宫颈上皮内瘤变和20例正常宫颈组织中的表达。结果 RRM1在正常宫颈组织、宫颈上皮内瘤变和宫颈癌组织中都有不同程度的表达,但宫颈癌组织中RRM1的表达(93.7%,75/80)明显高于宫颈内瘤变(46.7%,14/30)和正常宫颈组织(10.0%,2/20),且宫颈癌组织分化程度越低则RRM1的阳性率越高,表达强度越强(P<0.01);RRM1的表达与宫颈癌临床分期无关(P>0.05);不同组织类型的宫颈癌RRM1的表达差异无统计学意义(P>0.05);RRM1的阳性表达与有无淋巴结转移无关(P>0.05)。结论 RRM1在宫颈癌组织中的表达与宫颈癌组织分化的高低有关。RRM1在宫颈癌的发生发展中起重要作用,有望成为宫颈癌新的早期诊断指标。 Objective To study the expression of RRM1 in uterine cervical cancer tissue and explore the relationship with the development of uterine cervical cancer.Methods The expression of RRM1 was detected by immunohistochemistry staining in 80 specimens of cervical cancer,30 specimens of CIN and 20 specimens of normal cervical tissue.Results The expression of RRM1 was significantly higher in uterine cervical cancer tissue（93.7%,75/80）than that in CIN（46.7%,14/30）and normal cervical tissue（10.0%,2/20）（P〈0.05）.The much higher expressions of RRM1 could be detected in low differentiation uterine cervical cancer tissue（P〈0.01）.The expression of RRM1 had no significant difference with pathological types,clinical stages and with or without lymph node metastasis（P〉0.05）.Conclusion The expression of RRM1 in uterine cervical cancer tissue is related to differentiations.RRM1 seems to play important roles in carcinogenesis and progress of uterine cervical cancer and could be a new marker for early diagnose.
作者 刘爱华 王黎明
机构地区 山东省青岛大学医学院附属医院妇产科 蓬莱市人民医院妇产科
出处 《中国实用医药》 2011年第9期1-3,共3页 China Practical Medicine
关键词 宫颈癌 宫颈上皮内瘤变 RRM1 免疫组织化学 Uterine cervical cancer Cervical intraepithelial neoplasis RRM1 Immunohistochemistry
分类号 R737.33 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Guittet O,Hkansson P,Voevodskaya N,et al.Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein,which is expressed both in resting cells in response to DNA damage and in proliferating cells.J Biol Chem,2001,276(44):40647-40651.
  • 2EngstromY,Rozell B.Immunocytochemical evidence for the cytoplasmic localization and differential expression during the cell cycle of the M1 and M2 subunits of mammalian ribonucleotide reductase.EMBOJ,1988,7(6):1615-1620.
  • 3Lo Muzio LL,Farina A,Robini C,et al.Survivin as prognostic factor in squamous cell carcinoma of the oral cavity.Cancer Lett,2005,225(1):27-33.
  • 4Bhoumik A,Takahashi S,Breitweiser W,et al.ATM-dependent phosphorylation of ATF2 is required for the DNA damage response.Mol Cell,2005,18(5):577-587.
  • 5Reichard P.Ribonucleotide reductases:the evolution of allosteric regulation.Arch Biochem Biophys,2002,397(2):149-155.
  • 6Kolberg M,Strand KR,Graff P,et al.Structure,function,and mechanism of ribonucleotide reductases.Biochim Biophys Acta,2004,1699(12):1-34.
  • 7Bepler G,Sharma S,Cantor A,et al.RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-smallcell lung cancer.J Clin Oncol,2004,22(10):1878-1885.
  • 8Zheng Z,Chen T,Li XL,et al.DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.N Eng J Med,2007,356:800-808.
  • 9Davidson JD,Ma L,Flagella M,et al.An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.Cancer Res,2004,64(11):3761-3766.

同被引文献39

  • 1要洁,林晨,冯奉仪,张雪燕,付明,梁萧,吴世凯,董梅,宋海峰,钱海利,杨莹.人胰腺癌吉西他滨耐药细胞系的建立及耐药特性的检测[J].实用肿瘤杂志,2005,20(3):199-203. 被引量：4
  • 2ALEXAKIS N, HALLORAN C, RARATY M, et al. Current standards of surgery for pancreatic cancer [J] . Br J Surg, 2004 , 91(11) :1410-1427.
  • 3BURRIS H A ill, MOORE M J , ANDERSEN J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [J]. J Clin Oncol, 1997,15 :2403-2413.
  • 4V ALSECCHI ME, HOLDBROOK T, LEIBY BE, et al. Is there a role for the quantification of RRMI and ERCCI expression in pancreatic ductal adenocarcinoma [J]. BMC Caneer,2012,12(3) :104.
  • 5ABBRUZZESE J 1. New applications of gemcitabine and future directions in the management of pancreatic cancer [J] . Caneer,2002,95 (4 Suppl) :941-945.
  • 6SMITH B D, JUDITH E. Ribonucleotide reductase: an old target with new potential [J]. Leuk Res, 2003,27 ( 12) : 1075- 1076.
  • 7BERGMAN AM, EIJ K P P, RUIZ- van- HAPEREN V W, et al. In vivo induction of resistance to gemcitabine resultsin increased expression of ribonucleotide reductase subunit Ml as the major determinant [J] . Cancer Res, 2005 ,65 (20) : 9510- 9516.
  • 8GOAN Y G, ZHOU B, HU E, et al. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2- difluorodeoxycytidine in the human KB cancer cell line [J] . Cancer Res, 1999 ,59(17) :4204-4207.
  • 9LEE J J, MAEN G C H, BAEK S K, et al. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit Ml (RRMl) protein is a predictor of shorter survival to gemcitahine- based chemotherapy in advanced non- small cell lung cancer( NSCLC) [J]. Lung Cancer, 2010,70 (2) : 205-210.
  • 10REYNOLDS C, OBASAJU C, SCHELL M J, et al. Randomized phase III trial of gemcitahine- based chemotherapy with in situ RRMI and ERCCI protein levels for response prediction in non-small-cell lung cancer[J]. J Clin Oncol,2009, 27(34) :5808-5815.

引证文献3

二级引证文献5

中国实用医药
2011年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部